Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-24
2007-07-24
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000
Reexamination Certificate
active
10276752
ABSTRACT:
The invention features recombinant viral vectors that take advantage of the activity of picornaviral protein 3A in modulating cytokine secretion and antigen presentation on MHC Class I (MHC I), which in turn provides for modulation of a Th1-mediated immune response to the transfected host cell. Specifically, a recombinant viral vector comprising a sequence encoding picornaviral protein 3A provides for decreased antigen presentation on MHC I and a decreased incidence of Th1-mediated immune response, while a recombinant picornaviral vector that is deficient in protein 3A production provides for increased cytokine secretion, increased antigen presentation on MHC I and increased Th1-mediated immune response towards the transfected host cell. The invention also features methods of inducing humoral or cellular immunity using the vectors.
REFERENCES:
patent: 5622705 (1997-04-01), Morrow
patent: 6015694 (2000-01-01), Dubensky et al.
patent: 6589531 (2003-07-01), Andino-Pavlovsky et al.
patent: 6680169 (2004-01-01), Morrow et al.
patent: 6866853 (2005-03-01), Egorov et al.
patent: 6893643 (2005-05-01), Andino-Pavlovsky et al.
Choe et al, Virol 2005; 18-29.
Doedens et al, J Virol 1997;71:9054-64.
Crotty et al, J Virol 1999;73:9485-95.
Deonarain, 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Miller et al, 1995, FASEB J., vol. 9, pp. 190-199.
Makrides et al, Protein Exp Pur 1999;17:183-202.
Zink et al, Gene Ther Mol Biol Jan. 2001;6:1-24.
French Anderson, Hum Gene Ther 2002;13:1261-2.
Weiss, Washington Post Mar. 2005.
Hewson, “RNA Viruses: Emerging Vectors for Vaccination and Gene Therapy,” (2000) Mole. Med. Today 6:28-35.
Aldabe et al., “Induction of Membrane Profileration by Poliovirus Proteins 2C and 2BC,” (1995) Biochem. Biophys. Res. Commun. 206:64-76.
Bienz et al., “Association of Polioviral Proteins of the P2 Genomic Region with the Viral Replication Complex and Virus-Induced Membrane Synthesis as Visualized by Electron Microscopic Immunocytochemistry and Autoradiography,” (1987) Virology 160:220-226.
Cho et al., Membrane Rearrangement and Vesicle Induction by Recombinant Poliovirus 2C and 2BC in Human Cells, (1994) Virology 202:129-145.
Dales et al., “Electron Microscopic Study of the Formation of Poliovirus,” (1965) Virology 26:379-389.
Doedens et al., “Inhibition of Cellular Protein Secretion by Poliovirus Proteins 2B and 3A,” (1995) Embo J. 14:894-907.
Bienz et al., “Structural and Functional Characterization of the Poliovirus Replication Complex,” (1992) J. Virology 66:2740-2747.
Bienz et al., “Characteristics of the Poliovirus Replication Complex,” (1994) Arch. Virol. Suppl. 9:147-157.
Bernstein et al., “Poliovirus Mutant that Contains a Cold-Sensitive Defect in Viral RNA Synthesis,” (1988) J. Virol. 62:2922-2928.
Andino et al., “Engineering Poliovirus as a Vaccine Vector for the Expression of Diverse Antigens,” (1994) Science 265:1448-1451.
Burke et al., “Antigen Chimaeras of Poliovirus as Potential New Vaccines,” (1988) Nature 332:81-82.
Mattion et al., “Attenuated Poliovirus Strain as a Live Vector: Expression of Regions of Rotavirus Outer Capsid Protein VP7 by Using Recombinant Sabin 3 Viruses,” (1994) J. Virol. 68:3925-3933.
Ansardi et al., Characterization of Poliovirus Replicons Encoding Carcinoembryonic Antigen (1994) 54:6359-6364.
Dietz S.B. et al., “MHC I-Dependent Antigen Presentation is Inhibited by Polivirus Protein, 3a”, Proc. Natl. Acad. Sci., Dec. 2000, (97) No. 25 pp. 13790-13795.
Gern, J.E. et al. Rhinovirus Inhibits Antigen-Specific T Cell Proliferation Through an Intercellular Adhesion Molecule-1-Dependant Mechanism. J. Infect. Dis. 1996, (174), pp. 1143-1150.
Louis Alexander et al. “Polioviruses Containing Picomavirus Type 1 and/or Type 2 Internal Ribosomal Entry Site Elements: Genetic Hybrids and the Expression of a Foreign Gene”, Pro. Nat. Acad. Sci. USA vol. 91, pp. 1406-1410 (Feb. 1994).
John R. Doedens et al. “Inhibition of Endoplasmic Reticulum-to-Golgi Traffic by Poliovirus Protein 3A: Genetic and Ultrastructural Analysis”, Journal of Virology, vol. 7, No. 12, pp. 9054-9064, (Dec. 1997).
Stefanie Mandl et al. “Polivirus Vaccine Vectors Elicit Antigen-Specific Cytotoxic T Cells and Protect Mice Against Lethal Challenge with Malignant Melanoma Cells Expressing a Model Antigen”, Proc. Natl. Acad. Sci. USA vol. 95, pp. 8216-8221 (Jul. 1998).
Pak Phi Poon et al. “Retrograde Transport from the Yeast Golgi is Medicated by two ARF GAP Proteins With Overlapping Function”, The Embo Journal vol. 18, No. 3, pp. 555-564 (1999).
Andreas Schlegel et al. “Cellular Origin and Ultrastructure of Membranes Induced During Poliovirus Infection”, Journal of Virology, vol. 70, No. 10, pp. 6576-6588 (Oct. 1996).
Deitz Stephen B.
Dodd Dana A.
Doedens John
Kirkegaard Karla
Bozicevic Field & Francis LLP
Francis Carol L.
Li Q. Janice
LandOfFree
Viral vectors useful in induction of humoral or cellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral vectors useful in induction of humoral or cellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vectors useful in induction of humoral or cellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803274